Amneal Pharmaceuticals (NASDAQ:AMRX) has received FDA approval for its generic version of the GLP-1 agonist diabetes drug Byetta and resubmitted its New Drug Application for a prefilled syringe ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat ... and available under the brand name Byetta, or with a placebo. While it is one of the GLP-1 ...

Medication for weight loss is very popular ... starting with the approval of Byetta, with follow-on products continually improving on efficacy. The most recent, Ozempic and Mounjaro, offer significant ...

The drugs selected for the report include Mounjaro, Rybelsus, Ozempic, Trulicity, Bydureon, Victoza, Byetta, Invokana, Jardiance and Farxiga. Currently, Medicare Part D covers diabetes drugs for ...

This Copenhagen-based biotech is developing a peptide analog of Amylin's Byetta (glucagon-like peptide ... so they're well-positioned if any of their drugs work.” The nearest competitor, she ...

Two such drugs are currently approved — exenatide (Byetta; Amylin/Eli Lilly and Company) and liraglutide (Victoza; NovoNordisk) — both of which are administered by injection. This success has ...

Medication for weight loss is very popular ... starting with the approval of Byetta, with follow-on products continually improving on efficacy. The most recent, Ozempic and Mounjaro, offer ...

Medication for weight loss is very popular ... starting with the approval of Byetta, with follow-on products continually improving on efficacy. The most recent, Ozempic and Mounjaro, offer ...